0
Abstract: Slide Presentations |

SARCOIDOSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (SAPAH): CHARACTERISTICS OF PATIENTS ENROLLED IN A PROSPECTIVE, OPEN LABEL TRIAL OF INHALED ILOPROST FREE TO VIEW

Robert P. Baughman, MD*; Peter J. Engel, MD; Elyse E. Lower, MD; Kristin Highland, MD; Marc A. Judson, MD
Author and Funding Information

University of Cincinnati, Cincinnati, OH


Chest


Chest. 2007;132(4_MeetingAbstracts):482a. doi:10.1378/chest.132.4_MeetingAbstracts.482a
Text Size: A A A
Published online

Abstract

PURPOSE: Sarcoidosis associated pulmonary hypertension (SAPAH) can lead to significant dyspnea which may be unresponsive to immunosuppressive therapy. Recent case reports have demonstrated that SAPAH may respond to vasodilator therapy, including intravenous epoprostenol.

METHODS: We have initiated a prospective open-label study to evaluate the benefit of inhaled iloprost 2.5 to 5.0 mcg six times a day in patients with SAPAH. Right heart catheterization is performed prior to and after 16 weeks of therapy. Six minute walk distance (6MWD) is determined prior to and monthly throughout the study.

RESULTS: To date, 12 sarcoidosis patients have been enrolled in this two center study. Patient demographics include 10 African Americans, 6 women, and age 52 (41-64) years (Median (Range)). Of these 12, 7 were classified as WHO class 3, the others WHO class 2. The baseline hemodynamic values include PA systolic pressure was 59 (45-70) Torr, PA mean= 36 (27-50) Torr, cardiac output= 5.5 (3.5-9.5) liters/min. Baseline 6 minute walk distance (6MWD) was 335 (23-478) m. Follow up studies have been performed on four patients. Three patients had a documented fall in PA mean (1.7, 6.7, and 13.3 Torr) while one patient had a rise in PA mean (4.3 Torr). Three patients had an increase in their 6MWD (30, 46, and 53 m), while one patient had a fall in 6MWD, but had a decrease in her PA mean of 6.7 Torr. To date, two patients discontinued drug because of severe cough.

CONCLUSION: SAPAH can be a significant reason for reduced 6MWD. Inhaled iloprost was effective in improving hemodynamics and 6MWD in some patients with SAPAH.

CLINICAL IMPLICATIONS: Reduction in 6MWD due to SAPAH may respond to pulmonary vasodilator therapy, including inhaled iloprost.

DISCLOSURE: Robert Baughman, Grant monies (from industry related sources) From Actelion to support this trial; Consultant fee, speaker bureau, advisory committee, etc. Actelion speaker bureau; Product/procedure/technique that is considered research and is NOT yet approved for any purpose. Iloprost is not approved for SAPAH

Tuesday, October 23, 2007

2:30 PM - 4:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543